The journal publishes evidence-based content on the detection, prevention, diagnosis, and treatment of cancerous growths in women and includes peer-reviewed original research, reviews and opinion pieces on topics such as ovarian cancer, cervical cancer and diagnostics.
The journal’s main audience is gynecologists and gynecological oncologists, but it is also relevant to surgeons, oncologists and research scientists, and is the official publication of the International Gynecologic Cancer Society (IGCS) and European Society of Gynaecological Oncology (ESGO).
New features included in the move to BMJ are lead article podcasts, consensus statements, protocols for prospective clinical trials, and review articles that highlight and summarize the most up-to-date information in women’s cancer. Additionally, the journal will feature case studies focusing on expert opinions on management of complex clinical scenarios, educational videos and congress proceedings.
The new Editor-in-Chief for 2019, Dr. Pedro Ramirez, says: “IJGC is essential to the medical field and to gynecologic oncologists around the world because it provides the latest research in the area of women’s cancer with a focus on highlighting the work being done not only in developed countries, but also in numerable centers in underserved regions of the world.”
Peter Ashman, Chief Executive Officer of BMJ, says: “IJGC publishes high quality research in women’s cancer to help gynecologists provide the best quality care to their patients. As part of our vision for a healthier world, BMJ is very pleased to enter into a partnership with the IGCS and ESGO and will bring its world-renowned focus on excellence in publishing to the partnership. We look forward to working with Dr. Ramirez, the editorial team and the Societies on this very prestigious journal.”
